Sorafenib in advanced hepatocellular carcinoma.

@article{Llovet2008SorafenibIA,
  title={Sorafenib in advanced hepatocellular carcinoma.},
  author={Josep M Llovet and Sergio Ricci and Vincenzo Mazzaferro and Philip Hilgard and Edward J. Gane and Jean-Fr{\'e}d{\'e}ric Blanc and Andr{\'e} Cosme de Oliveira and Armando Santoro and J I Raoul and Alejandro Forner and Maxwell Schwartz and Camillo Porta and Stefan Zeuzem and Luigi Bolondi and Tim F Greten and Peter R. Galle and J E Seitz and Ivan Borbath and Dieter H{\"a}ussinger and Tom Giannaris and Minghua Shan and Marius Moscovici and Dimitris Voliotis and Jordi Bruix},
  journal={The New England journal of medicine},
  year={2008},
  volume={359 4},
  pages={378-90}
}
BACKGROUND No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma. METHODS In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

7 Figures & Tables

Connections & Topics

Mentioned Connections BETA
A preliminary study suggested that sorafenib , an oral multikinase inhibitor of the vascular endothelial growth factor receptor , the platelet - derived growth factor receptor , and Raf may be effective in hepatocellular carcinoma .
All Topics